Eiger BioPharmaceuticals Investor Relations Material

Latest events

Status Update

Eiger BioPharmaceuticals

Q4 2023

8 Apr, 2024

Q3 2023

9 Nov, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies

Latest reports from Eiger BioPharmaceuticals Inc

Access all reports
Eiger BioPharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases. The company’s therapeutic areas include infectious diseases, metabolic disorders, and genetic conditions. Eiger’s pipeline targets diseases with high unmet medical needs, and it works to bring new treatment options to patients who have limited alternatives. Its approach involves repurposing existing drugs and developing novel compounds to advance its treatment options through clinical trials and regulatory approvals. The company is headquartered in Palo Alto, California, and its shares are listed on the NASDAQ.